<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998685</url>
  </required_header>
  <id_info>
    <org_study_id>550</org_study_id>
    <nct_id>NCT01998685</nct_id>
  </id_info>
  <brief_title>Prothrombotic Factors and Anaesthesia in Prostate Cancer</brief_title>
  <official_title>Prothrombotic Factors , Angiogenic Growth Factor and Different Anaesthetic Techniques in Cancer Patients Undergoing Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess if different anesthetic techniques can affect coagulant factors in
      patients with prostate cancer undergoing elective laparoscopic radical prostatectomy (LRP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The utility of anti-thrombotic prophylaxis in cancer patients undergoing laparoscopic radical
      prostatectomy (LRP) is still controversial. Moreover, different anaesthetic techniques could
      modify coagulant factors. Thus, in this study we will be to investigate the variations of
      pro- and anti-coagulant and fibrinolytic factors in two established types of anaesthesia in
      patients with prostate cancer undergoing elective LRP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of rate of prothrombotic markers and Vascular Endothelial Growth Factor (VEGF) variation</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free-desease survivall</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Prostatic Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Balanced (BAL) anaesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 Î¼g kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Totally Intravenous Anesthesia (TIVA-TCI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Totally Intravenous Anesthesia (TIVA-TCI)</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanyl</intervention_name>
    <arm_group_label>Totally Intravenous Anesthesia (TIVA-TCI)</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Balanced (BAL) anaesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Balanced (BAL) anaesthesia</arm_group_label>
    <other_name>Fentanest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>Balanced (BAL) anaesthesia</arm_group_label>
    <other_name>Sevorane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed cancer of the prostate

          -  histological Gleason score evaluation.

        Exclusion Criteria:

          -  ASA &gt;2

          -  metabolic equivalent task &lt; 4

          -  BMI&gt;30

          -  no pre-operative pharmacological thromboprophylaxis and/or anti-coagulant therapy

          -  history of abnormal bleeding, or abnormal coagulant factors

          -  sepsis within the last 2 weeks

          -  previous new adjuvant treatments (chemo, hormone, and radiotherapy)

          -  non-steroid , anti-inflammatory and statins drugs for at least 2 wks before surgery

          -  venous or arterial thromboembolism within the last 3 months, peripheral venous disease

          -  neurological disease with extremity paresis

          -  chronic liver disease

          -  pre-operative haemoglobin concentration &lt; 9 mg dl-1

          -  prolonged duration of surgery (&gt;3 hrs)

          -  peri-operative blood transfusion

          -  not adequate material for laboratory testing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ester Forastiere, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anaesthesiology, Regina Elena, National Cancer Institute, Via Elio Chianesi 53, 00144 Roma (Italy); Tel. +39 0652662942, FAX: +39 0652662993; e-mail: forastiere@ifo.it</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anaesthesiology, Regina Elena, National Cancer Institute</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ester Forastiere</investigator_full_name>
    <investigator_title>chief</investigator_title>
  </responsible_party>
  <keyword>Prostatectomy</keyword>
  <keyword>Coagulation Factor</keyword>
  <keyword>Balanced Anesthesia</keyword>
  <keyword>Intravenous Anesthesia,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

